<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159081</url>
  </required_header>
  <id_info>
    <org_study_id>01GI 9932 - P 2.2.2.1 / 1</org_study_id>
    <nct_id>NCT00159081</nct_id>
  </id_info>
  <brief_title>One Year Drug Treatment in First-Episode Schizophrenia</brief_title>
  <official_title>One Year Maintenance Treatment With Low Dose Haloperidol vs. Risperidone in First-Episode Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Research Network On Schizophrenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Humboldt-Universität zu Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mainz University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, double-blind, multi-center study on 1 year course and treatment
      outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in
      first-episode schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this multi-center study is to optimize the long-term treatment of patients
      with first episode schizophrenia. This investigation should contribute to the issue of
      effective relapse prevention in first-episode patients. 1-year maintenance neuroleptic
      treatment is done with low dose haloperidol or risperidone (target dose 2-4 mg/die).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>course in psychopathology</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>social and cognitive functioning</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side-effects</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drop-out</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance antipsychotic treatment with risperidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintenance antipsychotic treatment with haloperidol in low-dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol, Risperidone (drug)</intervention_name>
    <description>targeted dose of 2-4 mg/day over 1 year</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  After the acute treatment of the first-episode in schizophrenia (according ICD-10 F20)

          -  Age between 18 and 55

          -  Informed consent

        Exclusion Criteria:

          -  Residence outside of the catchment area

          -  Legal reasons

          -  Insufficient knowledge of the German language

          -  Substance abuse or addiction

          -  Pregnancy

          -  Serious physical illness

          -  Organic brain disease

          -  Contraindication to neuroleptic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Gaebel, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Psychiatry and Psychotherapy, University of Duesseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy at the Heinrich-Heine-University</name>
      <address>
        <city>Duesseldorf</city>
        <state>North Rhine-Westphalia</state>
        <zip>40629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-schizophrenie.de</url>
    <description>Click here for more information about this study: One year maintenance treatment with low dose Haloperidol vs. Risperidone in first-episode schizophrenia</description>
  </link>
  <reference>
    <citation>Gaebel W, Möller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wölwer W, Von Wilmsdorff M, Bottlender R, Klingberg S. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004 Apr;254(2):129-40.</citation>
    <PMID>15146342</PMID>
  </reference>
  <results_reference>
    <citation>Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ; German Study Group on First-Episode Schizophrenia. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2007 Nov;68(11):1763-74.</citation>
    <PMID>18052570</PMID>
  </results_reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>February 6, 2008</last_update_submitted>
  <last_update_submitted_qc>February 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2008</last_update_posted>
  <keyword>Schizophrenia</keyword>
  <keyword>first episode</keyword>
  <keyword>long-term treatment</keyword>
  <keyword>typical vs. atypical neuroleptics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

